Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemoradiation for Resectable Stage 3A NSCLC
NCT02987998Phase 1Terminated
- Start
- May 2017
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC). Primary endpoint: Number of patients with grade 3 pulmonary toxicity or grade 4 other non hematologic toxicity up to 5 years. Started May 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02987998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987998.